In a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...
Read MoreBreast cancer Posts on Medivizor
Mindfulness-based interventions in cancer patients and survivors
In a nutshell This review aimed to summarize available data about the effectiveness of mindfulness-based interventions for cancer-related symptoms in cancer patients and survivors. This review concluded that mindfulness-based interventions can have a beneficial effect as an adjuvant therapy in these patients. Some background...
Read MoreChemotherapy in patients with hormone receptor positive, node positive invasive breast cancer
In a nutshell This study wanted to find out how well chemotherapy for invasive breast cancer works, especially in those over 70 years old. The study found that most patients benefit from chemotherapy, however, those aged over 70 benefited less of this treatment than those aged under 70. Some background Most types of breast cancer have guidelines with...
Read MoreAdding targeted therapy to chemotherapy and surgery in patients with breast cancer
In a nutshell This study wanted to find out if adding targeted therapies to chemotherapy before surgery improved outcomes in patients with breast cancer. The study found that patients responded to treatment better when a targeted therapy was added to chemotherapy and surgery treatment. Some background There are multiple ways to treat breast...
Read MoreSafety and effectiveness of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
In a nutshell This study aimed to investigate the effectiveness and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. This study concluded that this combination was found to be safe and promising in these patients. Some background Pembrolizumab (Keytruda) is a targeted...
Read MorePalbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer
In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. This study concluded that palbociclib and endocrine therapy is more effective than...
Read MoreMy Oncologist Doesn’t Believe Food Is Necessary
By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...
Read MoreThe effect of fertility preservation on disease free survival in patients with invasive breast cancer
In a nutshell This study aimed to investigate if fertility preservation in patients with invasive breast cancer would affect disease-free survival. This study concluded that fertility preservation appears unlikely to affect disease-free survival in these patients. Some background Fertility preservation (FP) is the process of saving or...
Read MoreTrastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for HER2+ advanced breast cancer
In a nutshell This study wanted to find out which treatment resulted in better overall survival for patients with HER2+ breast cancer; trastuzumab emtansine (Kadcycla) with or without pertuzumab (Perjeta), or trastuzumab (Herceptin) plus a taxane. The study found that the overall survival was similar across...
Read MoreLooking for patients with advanced triple negative breast cancer to test an experimental drug with three functions
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read MoreComparing 6- and 12-month trastuzumab treatment after surgery for early breast cancer
In a nutshell This study aimed to compare the outcomes for patients with early breast cancer who received 6- or 12-months trastuzumab after surgery. This study concluded that the standard duration of trastuzumab after surgery should remain 12 months. Some background Trastuzumab (Herceptin) is a targeted...
Read MoreSearching for patients with early breast cancer to trial a partial-radiation treatment
In a nutshell This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States. The...
Read More
